Vertex Pharmaceuticals Inc (VRTX) Com Stk

Sell:$484.27Buy:$484.65$3.91 (0.81%)

NASDAQ:2.20%
Market closed | Prices delayed by at least 15 minutes
Sell:$484.27
Buy:$484.65
Change:$3.91 (0.81%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$484.27
Buy:$484.65
Change:$3.91 (0.81%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Key people

Jeffrey M. Leiden
Executive Chairman of the Board
Reshma Kewalramani
President, Chief Executive Officer, Director
Charles F. Wagner
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
David M. Altshuler
Executive Vice President - Global Research, Chief Scientific Officer
Carmen Bozic
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Amit K. Sachdev
Executive Vice President, Chief Patient and External Affairs Officer
Ourania Tatsis
Executive Vice President, Chief Regulatory and Quality Officer
Kristen Ambrose
Senior Vice President, Chief Accounting Officer
Joy Liu
Corporate Secretary
Bruce I. Sachs
Lead Independent Director
Sangeeta N. Bhatia
Independent Director
Lloyd A. Carney
Independent Director
Alan Garber
Independent Director
Michel Lagarde
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92532F1003
  • Market cap
    $121.14bn
  • Employees
    6,100
  • Shares in issue
    256.79m
  • Exchange
    NASDAQ
  • Index
    S&P 500, NASDAQ 100 Index, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.